Tanghetti Emil, Kircik Leon, Wilson David, Dhawan Sunil
Center for Dermatology and Laser Surgery, Sacramento, CA 95819, USA.
J Drugs Dermatol. 2008 Jun;7(6):534-8.
Benzoyl peroxide (BPO) is poorly soluble. A solubilized formulation of BPO has been developed to maximize its bioavailability and enhance follicular penetration.
Patients with acne vulgaris were randomly assigned to receive solubilized BPO 5% gel on one side of the face and a BPO 5%/clindamycin 1% combination product on the contralateral side, twice daily for 4 weeks.
Of 23 patients enrolled, 100% completed the study. Reductions in lesion count with the solubilized BPO gel were at least as great as with BPO/clindamycin--and significantly greater (P< or =.05) for noninflammatory lesions at week 1 and inflammatory lesions at week 4. Both regimens were generally well tolerated and patient satisfaction was comparable.
Solubilized BPO 5% gel monotherapy offers significantly greater efficacy, and comparable patient satisfaction, compared with BPO/clindamycin. The early reduction in lesion counts observed with the solubilized BPO gel in the absence of an antibiotic is clinically relevant.
过氧化苯甲酰(BPO)溶解度低。已开发出一种BPO的增溶制剂,以最大限度地提高其生物利用度并增强毛囊渗透。
寻常痤疮患者被随机分配,一侧面部使用5%增溶BPO凝胶,对侧面部使用5%BPO/1%克林霉素联合产品,每日两次,共4周。
23名入组患者全部完成研究。增溶BPO凝胶导致的皮损计数减少至少与BPO/克林霉素相当——在第1周非炎性皮损和第4周炎性皮损方面显著更大(P≤0.05)。两种治疗方案总体耐受性良好,患者满意度相当。
与BPO/克林霉素相比,5%增溶BPO凝胶单一疗法疗效显著更佳,患者满意度相当。在无抗生素情况下,增溶BPO凝胶早期导致的皮损计数减少具有临床意义。